March of the generic loratadines
This article was originally published in The Tan Sheet
Executive Summary
FDA approves a quartet of generic loratadine syrup products Aug. 20. Perrigo gets the nod for a 10 mg/10 ml strength, further building the firm's market-leading generic loratadine franchise 1("The Tan Sheet" Aug. 16, 2004, p. 4). Morton Grove, Ranbaxy and Taro receive approval for 5 mg/mL strength...
You may also be interested in...
Perrigo Says Rx Generic Pursuits Will Strengthen OTC Private Label Business
Perrigo's move into prescription generics will further enhance its market-leading position in private label over-the-counter and Rx-to-OTC switch drugs, the firm claims
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.